Enibarcimab

恩巴瑞西单抗

Report date: 2026/04/26 20:00:14
First In Class

Base Information

Drug NameEnibarcimab
Drug Alias NameAdrecizumabHAM-8101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAdrenomedullin inhibitors
TargetsAdrenomedullin
Therapy Area/IndicationsVascular DiseasesShock, CardiogenicShock, Septic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumNetherlandsGermany +[4
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAdrenomed Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsVascular DiseasesShock, CardiogenicShock, Septic

Other Information

ATC CodeN/A
Related LinksN/A